CDKN2A and pancreatic adenocarcinoma: Higher genetic mutations were found in patients from the high-risk group, such as KRAS, TP53, SMAD4, and CDKN2A, which were major drivers of PAAD (Jones et al., 2008; Waddell et al., 2015; Makohon-Moore and Iacobuzio-Donahue, 2016).